The Treatment Episode Data Set -- Admissions (TEDS-A) is a national census data system of annual admissions to substance abuse treatment facilities. TEDS-A provides annual data on the number and characteristics of persons admitted to public and private substance abuse treatment programs that receive public funding. The unit of analysis is a treatment admission. TEDS consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.

A sister data system, called the Treatment Episode Data Set -- Discharges (TEDS-D), collects data on discharges from substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.

TEDS variables that are required to be reported are called the "Minimum Data Set (MDS)", while those that are optional are called the "Supplemental Data Set (SuDS)".

Variables in the MDS include: information on service setting, number of prior treatments, primary source of referral, gender, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008).

Substances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.

Created variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.

This study has 1 Data Set.

The California Drug and Alcohol Treatment Assessment

(CALDATA) was designed to study the costs, benefits, and effectiveness

of the state's alcohol and drug treatment infrastructure (recovery

services) and specifically to assess (1) the effects of treatment on

participant behavior, (2) the costs of treatment, and (3) the economic

value of treatment to society. Data were collected on participants

(clients) across four types of treatment programs, or modalities:

residential, residential "social model," nonmethadone outpatient, and

outpatient methadone (detoxification and maintenance). Data were

collected in two phases. In Phase 1, treatment records were abstracted

for clients who received treatment or were discharged between October

1, 1991, and September 30, 1992. In Phase 2, these clients were

located and recruited for a follow-up interview. The CALDATA design

and procedures included elements from several national treatment

outcome studies including the Drug Services Research Survey, Services Research Outcomes Study, National

Treatment Improvement Evaluation Study, and Drug Abuse

Treatment Outcome Study. The record abstract was designed

to collect identifying and locating information for interview

reference during the personal interviewing phase. The abstract also

collected demographic, drug, or alcohol use, and treatment and service

information. The follow-up questionnaire covered time periods before,

during, and after treatment and focused on topics such as ethnic and

educational background, drug and alcohol use, mental and physical

health, HIV and AIDS status, drug testing, illegal activities and

criminal status, living arrangements and family issues, employment and

income, and treatment for drug, alcohol, and mental health

problems. Drugs included alcohol, barbiturates, benzodiazepines,

cocaine powder, crack, downers, hallucinogens, heroin, illegal

methadone, inhalants, LSD, marijuana/hashish/THC, methamphetamines and

other stimulants, narcotics, over-the-counter drugs, PCP, ritalin or

preludin, and sedatives/hypnotics. CALDATA was originally known as the

California Outcomes Study (COS).This study has 1 Data Set.